Systemic and periocular deliveries of plasminogen kringle 5 reduce vascular leakage in rat models of oxygen-induced retinopathy and diabetes

Current Eye Research

Volumn 30, Issue 8, 2005, Pages 681-689

  Zhang, Sarah X ^a   Sima, Jing ^a   Wang, Joshua J ^a   Shao, Chunkui ^a   Fant, James ^a   Ma, Jian Xing ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b BSEB 328B ^*  (United States)

Author keywords

Diabetic retinopathy; K5; Macular edema; Permeability; VEGF

Indexed keywords

PLASMINOGEN; PROTEIN PLASMINOGEN KRINGLE 5; STREPTOZOCIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DOWN REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA; RETINA BLOOD VESSEL; RETINOPATHY; STREPTOZOCIN DIABETES; TREATMENT OUTCOME; VASCULAR FRAGILITY; VASCULAR LEAKAGE; VISUAL IMPAIRMENT;

ANIMALS; ANIMALS, NEWBORN; CAPILLARY PERMEABILITY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG ADMINISTRATION ROUTES; IMMUNOENZYME TECHNIQUES; OXYGEN; PEPTIDE FRAGMENTS; PLASMINOGEN; RATS; RATS, INBRED BN; RETINA; RETINAL DISEASES; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 24944589995     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680590934102     Document Type: Article

References (41)

1. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med. 1995;73:333-346.
2. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105:998-1003.
3. Bossi E, Koerner F. Retinopathy of prematurity. Intensive Care Med. 1995;21:241-246.
4. Klein R. Diabetic retinopathy. Annu Rev Public Health. 1996;17:137-158.
5. Cunha-Vaz JG, Gray JR, Zeimer RC, Mota MC, Ishimoto BM, Leite E. Characterization of the early stages of diabetic retinopathy by vitreous fluorophotometry. Diabetes. 1985;34:53-59.
6. Yoshida A, Ishiko S, Kojima M, Ogasawara H. Permeability of the blood-ocular barrier in adolescent and adult diabetic patients. Br J Ophthalmol. 1993;77:158-161.
7. Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes. 1998;47:401-406.
8. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest. 1996;74:819-825.
9. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo KT. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450.
10. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46:1473-1480.
11. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl. 2000;77:S113-119.
12. Antonetti DA, Lieth E, Barber AJ, Gardner TW. Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol. 1999;14:240-248.
13. Dvorak HF. VPF/VEGF and the angiogenic response. Semin Perinatol. 2000;24:75-78.
14. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci. 2001;42:2408-2413.
15. Ji WR, Barrientos LG, Llinas M, Gray H, Villarreal X, DeFord ME, Castellino FJ, Kramer RA, Trail PA. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem Biophys Res Commun. 1998;247:414-419.
16. Lu H, Dhanabal M, Volk R, Waterman MJ, Ramchandran R, Knebelmann B, Segal M, Sukhatme VP. Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells. Biochem Biophys Res Commun. 1999;258:668-673.
17. Chang Y, Mochalkin I, McCance SG, Cheng B, Tulinsky A, Castellino FJ. Structure and ligand binding determinants of the recombinant kringle 5 domain of human plasminogen. Biochemistry. 1998;37:3258-3271.
18. Castellino FJ, McCance SG. The kringle domains of human plasminogen. Ciba Found Symp. 1997;212:46-60.
19. Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinas M. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem. 1997;272:22924-22928.
20. Abumiya T, Lucero J, Heo JH, Tagaya M, Koziol JA, Copeland BR, del Zoppo GJ. Activated microvessels express vascular endothelial growth factor and integrin alpha(v)beta3 during focal cerebral ischemia. J Cereb Blood Flow Metab. 1999;19:1038-1050.
21. Zhang D, Kaufman PL, Gao G, Saunders RA, Ma JX. Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. Diabetologia. 2001;44:757-765.
22. Gao G, Li Y, Gee S, Dudley A, Fant J, Crosson C, Ma J-X. Downregulation of VEGF and up-regulation of PEDF: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem. 2002;277:9492-9497.
23. Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Sohndel S, McCance SG, O'Reilly MS, Llinas M, Folkman J. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem. 1996;271:29461-29467.
24. Zhang SX, Sima J, Shao C, Fant J, Chen Y, Rohrer B, Gao G, Ma J-x. Plasminogen kringle 5 reduces vascular leakage in the retina of rat model of the oxygen-induced retinopathy and diabetes. Diabetologia. 2004;47:124-131.
25. Kurz D, Ciulla TA. Novel approaches for retinal drug delivery. Ophthalmol Clin North Am. 2002;15:405-410.
26. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev. 2001;52:37-48.
27. Maurice D. Review: practical issues in intravitreal drug delivery. J Ocul Pharmacol Ther. 2001;17:393-401.
28. Tojo K, Isowaki A. Pharmacokinetic model for in vivo/in vitro correlation of intravitreal drug delivery. Adv Drug Deliv Rev. 2001;52: 17-24.
29. Ambati J, Gragoudas ES, Miller JW, You TT, Miyamoto K, Delori FC, Adamis AP. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000;41:1186-1191.
30. Loewenstein A, Zemel E, Vered Y, Lazar M, Perlman I. Retinal toxicity of gentamicin after subconjunctival injection performed adjacent to thinned sclera. Ophthalmology. 2001;108:759-764.
31. Einmahl S, Savoldelli M, D'Hermies F, Tabatabay C, Gurny R, Behar-Cohen F. Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest Ophthalmol Vis Sci. 2002;43:1533-1539.
32. Yanagi Y, Tamaki Y, Obata R, Muranaka K, Homma N, Matsuoka H, Mano H. Subconjunctival administration of bucillamine suppresses choroidal neovascularization in rat. Invest Ophthalmol Vis Sci. 2002;43:3495-3499.
33. Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthalmol. 2002;47:S41-52.
34. Koevary SB. Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond. Curr Drug Metab. 2003;4:213-222.
35. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
36. Gao G, Li Y, Fant J, Crosson CE, Becerra SP, Ma JX. Difference in ischemic regulation of vascular endothelial growth factor and pigment epithelium-derived factor in brown norway and sprague dawley rats contributing to different susceptibilities to retinal neovascularization. Diabetes. 2002;51:1218-1225.
37. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci. 2001;42:789-794.
38. Radius RL, Anderson DR. Distribution of albumin in the normal monkey eye as revealed by Evans blue fluorescence microscopy. Invest Ophthalmol Vis Sci. 1980;19:238-243.
39. Rohrer B, Stell WK. Localization of putative dopamine D2-like receptors in the chick retina, using in situ hybridization and immunocytochemistry. Brain Res. 1995;695:110-116.
40. Ambati J, Adamis AP. Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res. 2002;21:145-151.
41. Frohlich E. [Structure and function of blood-tissue barriers]. Dtsch Med Wochenschr. 2002;127:2629-2634.